Rarely has there been a more concerted effort by a country’s leadership to eliminate a source of national strength than the Biden administration’s war on fossil fuels.

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Drops for Eli Lilly and other influential companies are weighing on U.S. indexes. The S&P 500 slipped 0.3% Tuesday, even ...

At Disney's Fort Wilderness in Lake Buena Vista, FL, guests can enjoy the most affordable - and surprisingly magical - way to ...

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations, as wholesalers cut inventory after bulking up on supply in the previous ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025Dosing in the Heart-2 trial ...